BRCA1/2 testing in hereditary breast and ovarian cancer families II: Impact on relationships

被引:28
|
作者
McInerney-Leo, A
Biesecker, BB
Hadley, DW
Kase, RG
Giambarresi, TR
Johnson, E
Lerman, C
Struewing, JP
机构
[1] NHGRI, Med Genet Branch, Bethesda, MD 20892 USA
[2] NCI, Genet Epidemiol Branch, Bethesda, MD 20892 USA
[3] Westat Res, Rockville, MD USA
[4] Johns Hopkins Biostat Ctr, Baltimore, MD USA
[5] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA
[6] NCI, Lab Populat Genet, Bethesda, MD 20892 USA
关键词
family cohesion; conflict; expressiveness; genetic counseling; cancer risk testing;
D O I
10.1002/ajmg.a.30566
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Members of hereditary breast and ovarian cancer (HBOC) families often express concern during genetic counseling about the impact of BRCA1/2 testing on close relatives. Yet whether there are likely to be adverse effects of either the decision to undergo genetic testing or the results of testing on family relationships is unknown. One purpose of this study was to assess the impact on close family relationships. Within a randomized trial of breast cancer genetic counseling methods, members of 13 HBOC families were offered BRCA1/2 testing for a known family mutation. The Family Relationship Index (FRI) of the Family Environment Scale (FES) was used to measure perceived family cohesion, conflict, and expressiveness at baseline and again 6-9 months following the receipt of test results, or at the equivalent time for those who declined testing. Participants (n = 212) completed baseline and follow-up questionnaires. Comparisons were made between testers and non-testers as well as between those who tested positive and negative for the family mutation. One hundred eighty-one participants elected to undergo genetic testing (85%) and 47 (26%) were identified to have a mutation. After adjusting for baseline family relationship scores, counseling intervention, gender and marital status, non-testers reported a greater increase in expressiveness (P = 0.006) and cohesion (P = 0.04) than testers. Individuals who tested positive reported a decrease in expressiveness (P = 0.07), although as a trend. Regardless of test decision or test result, those who were randomized to a client-centered counseling intervention reported a decrease in conflict (P = 0.006). Overall, study results suggest that undergoing genetic testing and learning ones BRCA1/2 status may affect family relationships. Those individuals who declined testing reported feeling closer to family members and more encouraged to express emotions to other family members demonstrating potential benefit from the offer of testing. Since those who tested positive reported feeling less encouraged to express their emotions within the family, we recommend helping clients to identify others with whom they feel comfortable sharing their thoughts and feelings about their positive gene status and increased cancer risk. Published 2005 Wiley-Liss, Inc.
引用
收藏
页码:165 / 169
页数:5
相关论文
共 50 条
  • [11] Risk of ovarian cancer in BRCA1 and BRCA2 mutation negative hereditary breast cancer families
    Kauff, ND
    Mitra, N
    Robson, ME
    Hurley, KE
    Chuai, S
    Goldfrank, D
    Wadsworth, E
    Lee, J
    Cigler, T
    Borgen, PI
    Norton, L
    Barakat, RR
    Offit, K
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (18): : 1382 - 1384
  • [12] BRCA1 and BRCA2 Genetic Testing in Breast and/or Ovarian Cancer Families in Iran
    Keshavarzi, Fatemeh
    Javadi, Gholam Reza
    Nafissi, Nahid
    Akbari, Mohammad Esmail
    Yassaee, Vahid Reza
    Farzad, Maryam Sharafi
    Zeinali, Sirous
    YAKHTEH, 2010, 12 (03): : 329 - 340
  • [13] GENETIC TESTING IN BREAST OVARIAN-CANCER (BRCA1) FAMILIES
    WATSON, M
    MURDAY, V
    LLOYD, S
    PONDER, B
    AVERILL, D
    EELES, R
    LANCET, 1995, 346 (8974): : 583 - 583
  • [14] Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families
    Julian-Reynier, C
    Sobol, H
    Sévilla, C
    Noguès, C
    Bourret, P
    PSYCHO-ONCOLOGY, 2000, 9 (06) : 504 - 510
  • [15] Prevalence of BRCA1 and BRCA2 founder mutations in Brazilian hereditary breast and ovarian cancer families
    Ewald, I. P.
    Vargas, F. R.
    Moreira, M. A.
    Filho, C. M.
    da Cunha, D. R.
    Ramos, J. P.
    Ribeiro, P. L.
    Caleffi, M.
    Giugliani, R.
    Ashton-Prolla, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [16] Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer
    Buleje, Jose
    Guevara-Fujita, Maria
    Acosta, Oscar
    Huaman, Francia D. P.
    Danos, Pierina
    Murillo, Alexis
    Pinto, Joseph A.
    Araujo, Jhajaira M.
    Aguilar, Alfredo
    Ponce, Jaime
    Vigil, Carlos
    Castaneda, Carlos
    Calderon, Gabriela
    Gomez, Henry L.
    Fujita, Ricardo
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2017, 5 (05): : 481 - 494
  • [17] Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families
    Cierniková, S
    Tomka, M
    Kovác, M
    Stevurková, V
    Zajac, V
    NEOPLASMA, 2006, 53 (02) : 97 - 102
  • [18] Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families
    Novakovic, Srdjan
    Milatovic, Masa
    Cerkovnik, Petra
    Stegel, Vida
    Krajc, Mateja
    Hocevar, Marko
    Zgajnar, Janez
    Vakselj, Ales
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (05) : 1619 - 1627
  • [19] Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families
    Kim, TJ
    Lee, KM
    Choi, CH
    Lee, JW
    Lee, JH
    Bae, DS
    Kim, BG
    ONCOLOGY REPORTS, 2006, 15 (03) : 565 - 569
  • [20] BRCA1/2 testing in hereditary breast and ovarian cancer families:: Effectiveness of problem-solving training as a counseling intervention
    McInerney-Leo, A
    Biesecker, BB
    Hadley, DW
    Kase, RG
    Giambarresi, TR
    Johnson, E
    Lerman, C
    Struewing, JP
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2004, 130A (03) : 221 - 227